Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dose Escalation of Biosimilar Infliximab for RA Patients Deemed Cost Effective, to a Point

Publish date:: December 20, 2019

Key clinical point: The current low price of biosimilar infliximab makes it more cost effective at lower doses than golimumab in treating RA.

Major finding: After 18 months, 5% of golimumab patients increased their dose, compared with 49% of infliximab patients (P less than .0001).

Study details: A cohort analysis of 5,174 new infliximab users and 2,843 new golimumab users, all with RA.

Disclosures: Two of the four authors reported receiving research grants and consulting fees from various medical and pharmaceutical companies, and one other author reported owning stock in Amgen.

Citation:

Curtis JR et al. Arthritis Res Ther. 2019 Dec 12. doi: 10.1186/s13075-019-2022-8.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Rheumatoid Arthritis

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Tocilizumab, methotrexate combo equals tocilizumab alone for preventing progression,

Biomarker-based prognostic score identifies cardiovascular risk in RA,

Early life exposure to famine raises risk of RA in adulthood,